SMN2 and proximal spinal muscular atrophy: The antisense oligonucleotide nusinursen targets pre-mRNA splicing of the SMN2 gene, giving clinically meaningful benefits in the childhood ataxia, spinal muscular atrophy (SMA; Fig. 1C) [9].